AR015482A1 - Una composicion farmaceutica solida y soluble en agua que contiene un taxoide y una ciclodextrina, sus soluciones en disolventes acuosos para usoparenteral, un procedimiento para su preparacion, un metodo para prevenir la autoagregacion y la precipitacion prematura de un taxoide del grupo delpaclita - Google Patents
Una composicion farmaceutica solida y soluble en agua que contiene un taxoide y una ciclodextrina, sus soluciones en disolventes acuosos para usoparenteral, un procedimiento para su preparacion, un metodo para prevenir la autoagregacion y la precipitacion prematura de un taxoide del grupo delpaclitaInfo
- Publication number
- AR015482A1 AR015482A1 ARP980105607A ARP980105607A AR015482A1 AR 015482 A1 AR015482 A1 AR 015482A1 AR P980105607 A ARP980105607 A AR P980105607A AR P980105607 A ARP980105607 A AR P980105607A AR 015482 A1 AR015482 A1 AR 015482A1
- Authority
- AR
- Argentina
- Prior art keywords
- cyclodextrin
- pharmaceutical composition
- taxoid
- acetyl
- gamma
- Prior art date
Links
- 229920000858 Cyclodextrin Polymers 0.000 title abstract 8
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 title abstract 8
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 239000007787 solid Substances 0.000 title abstract 3
- 239000002904 solvent Substances 0.000 title 1
- 229940080345 gamma-cyclodextrin Drugs 0.000 abstract 4
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 abstract 4
- -1 for example Substances 0.000 abstract 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 abstract 2
- 229930012538 Paclitaxel Natural products 0.000 abstract 2
- 230000021736 acetylation Effects 0.000 abstract 2
- 238000006640 acetylation reaction Methods 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- 239000003125 aqueous solvent Substances 0.000 abstract 2
- 229960003668 docetaxel Drugs 0.000 abstract 2
- 229960001592 paclitaxel Drugs 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 238000006467 substitution reaction Methods 0.000 abstract 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 2
- 230000000593 degrading effect Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 238000007911 parenteral administration Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Una composicion farmacéutica solida y soluble en agua, que contiene un taxoide y una ciclodextrina, y sus soluciones en disolventes acuosos para usoparenteral, que: A) en calidad de ingrediente activo contienen un taxoide como el paclitaxel y docetaxel finamente disperso, de gran área superficial, amorfoy preferentemente liofilizado, eventualmente en la forma de sus sales o de sus hidratos polimorfos o solvatos como, por ejemplo, los solvatos formados conetanol y B) contienen una acetil-gamma-ciclodextrina o hidroxipropil-beta-ciclodextrina (llamadas de aquí en adelante ciclodextrina) finamente dispersa, degran área superficial, amorfa y preferentemente liofilizada, siendo la relacion ponderal entre el taxoide mencionado y la ciclodextrinamencionada de1:25 a 1:250; C) y eventualmente contienen otros materiales auxiliares solubles en agua y usualmente empleados en medicamentos destinados a la administracionparenteral. En particular, la composicion farmacéutica contiene en calidad de ingrediente activo paclitaxel y acetil-gamma-ciclodextrina en una relacionponderal de 1:100 a 1:150, o bien docetaxel e hidroxipropil-beta-ciclodextrina en una relacion ponderal de 1:25 a 1:100. La composicion farmacéutica puedecontener en calidad de ciclodextrina cualquiera de los siguientes componentes: acetil-gamma-ciclodextrina con un grado de acetilacion comprendido entreaproximadamente 2 y aproximadamente 12 grupos por anillo de ciclodextrina, acetil-gamma-ciclodextrina con un grado de acetilacion de aproximadamente 8 gruposacetilo por anillo de ciclodextrina, hidroxi-propil-beta-ciclodextrina con un grado de sustitucion comprendido entre aproximadamente 2 y aproximadamente 10grupos hidroxipropilo por anillo de ciclodextrina, hidroxi-propil-beta-ciclodextrina con un grado de sustitucion comprendido entre aproximadamente 4 yaproximadamente 6 grupos hidroxipropilo por anillo de ciclodextrina. Un procedimiento para preparar una composicion farmacéutica en estado solido einstantáneamente soluble como la mencionada más arriba, y sus soluciones en disolventes acuosos para uso parenteral, procedimiento en el cual: a) se disuelve
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU9701945A HUP9701945A3 (en) | 1997-11-10 | 1997-11-10 | Pharmaceutical composition for injection containing cyclodextrin and taxoids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR015482A1 true AR015482A1 (es) | 2001-05-02 |
Family
ID=89995733
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980105607A AR015482A1 (es) | 1997-11-10 | 1998-11-06 | Una composicion farmaceutica solida y soluble en agua que contiene un taxoide y una ciclodextrina, sus soluciones en disolventes acuosos para usoparenteral, un procedimiento para su preparacion, un metodo para prevenir la autoagregacion y la precipitacion prematura de un taxoide del grupo delpaclita |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US7671042B2 (es) |
| EP (1) | EP1059942B1 (es) |
| JP (1) | JP3656550B2 (es) |
| KR (1) | KR100607391B1 (es) |
| CN (1) | CN1222321C (es) |
| AR (1) | AR015482A1 (es) |
| AT (1) | ATE387916T1 (es) |
| AU (1) | AU742036B2 (es) |
| BR (1) | BR9814015A (es) |
| CA (1) | CA2309326C (es) |
| DE (1) | DE69839224T2 (es) |
| EA (1) | EA002776B1 (es) |
| HU (1) | HUP9701945A3 (es) |
| IL (1) | IL135990A0 (es) |
| NO (1) | NO329382B1 (es) |
| NZ (1) | NZ504098A (es) |
| PL (1) | PL199652B1 (es) |
| WO (1) | WO1999024073A1 (es) |
| ZA (1) | ZA989779B (es) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20020300A1 (es) | 2000-08-22 | 2002-05-10 | Pharmacia Corp | Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco |
| CA2454913A1 (en) * | 2001-08-20 | 2003-02-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | Parenteral formulations of 1-(5-tert-butyl-2-p-tolyl-2h-pryrazol-3-yl)-3-¬4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl|-urea and a cyclodextrin |
| CN100384865C (zh) * | 2001-11-02 | 2008-04-30 | 嵌入治疗公司 | 用于rna干扰的治疗用途的方法及组合物 |
| CA2495899A1 (en) * | 2002-08-15 | 2004-03-18 | Yunqing Liu | Solid nano pharmaceutical formulation and preparation method thereof |
| AR054215A1 (es) | 2006-01-20 | 2007-06-13 | Eriochem Sa | Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit |
| CN101020059B (zh) * | 2006-02-15 | 2011-01-05 | 中国科学院上海药物研究所 | 一种含多烯紫杉醇类物质的药物组合物及其制备方法 |
| KR100917809B1 (ko) * | 2006-05-22 | 2009-09-18 | 에스케이케미칼주식회사 | 우수한 저장안정성을 갖는 도세탁셀 함유 주사제 조성물 |
| WO2007142440A1 (en) * | 2006-06-02 | 2007-12-13 | Sk Chemicals Co., Ltd. | Stable pharmaceutical composition containing paclitaxel and a method of manufacturing the same |
| KR100917810B1 (ko) * | 2006-06-02 | 2009-09-18 | 에스케이케미칼주식회사 | 저장안정성이 우수한 파클리탁셀 함유 주사제 조성물 |
| CN100486645C (zh) | 2006-09-12 | 2009-05-13 | 南京师范大学 | 含有环糊精紫杉醇包合物的药物组合物及其制备方法 |
| CN100411688C (zh) * | 2006-09-12 | 2008-08-20 | 南京师范大学 | 含有环糊精/多烯紫杉醇包合物的药物组合物及其制备方法 |
| US20090022727A1 (en) | 2007-01-26 | 2009-01-22 | Alza Corp. | Injectable, nonaqueous suspension with high concentration of therapeutic agent |
| CN102014918A (zh) * | 2007-04-20 | 2011-04-13 | 太阳医药工业有限公司 | 由微量沉淀产生的药学组合物 |
| US20080319048A1 (en) * | 2007-06-22 | 2008-12-25 | Scidose Llc | Solubilized formulation of docetaxel without tween 80 |
| US20090087460A1 (en) * | 2007-10-02 | 2009-04-02 | Hamamatsu Photonics K.K. | Solid composition, microparticles, microparticle dispersion liquid, and manufacturing methods for these |
| AR063111A1 (es) | 2007-10-03 | 2008-12-30 | Eriochem Sa | Una formulacion farmaceutica de taxano |
| KR101502533B1 (ko) * | 2007-11-22 | 2015-03-13 | 에스케이케미칼주식회사 | 우수한 안정성을 갖는 택산 유도체 함유 주사제용동결건조 조성물 및 이의 제조방법 |
| KR101478779B1 (ko) * | 2007-11-22 | 2015-01-05 | 에스케이케미칼주식회사 | 재수화시간이 향상된 택산 유도체 함유 동결건조 조성물 및이의 제조방법 |
| EP2106786A1 (de) * | 2008-04-04 | 2009-10-07 | Roewer, Norbert, Univ.-Prof. Dr. med. | Pharmazeutische Zubereitung mit permethyliertem Cyclodextrin |
| US8912228B2 (en) | 2009-10-19 | 2014-12-16 | Scidose Llc | Docetaxel formulations with lipoic acid |
| KR20120130740A (ko) * | 2011-05-23 | 2012-12-03 | 에스케이케미칼주식회사 | 도세탁셀을 함유하는 액상 주사용 조성물 |
| US11406595B2 (en) * | 2012-05-21 | 2022-08-09 | University Of Maryland, College Park | Highly stable colloid from aqueous solutions of small organic molecules |
| US9925274B2 (en) | 2012-11-15 | 2018-03-27 | Sapiotec Gmbh | Delphinidin complex as an antiphlogistic or immunosuppressive active ingredient |
| CA2893881C (en) | 2012-12-11 | 2020-09-22 | Sapiotec Gmbh | Delphinidin for combating melanoma cells |
| CN105823810A (zh) * | 2016-01-04 | 2016-08-03 | 杭州电子科技大学 | 紫杉醇化疗效果检测装置及检测方法 |
| KR101829705B1 (ko) * | 2016-09-21 | 2018-02-19 | 씨제이헬스케어 주식회사 | 안정성이 향상된 주사용 조성물 |
| KR102262743B1 (ko) | 2017-07-07 | 2021-06-09 | 에이치케이이노엔 주식회사 | 주사용 조성물 |
| JP7274785B2 (ja) | 2018-07-25 | 2023-05-17 | ビカ バイオテクノロジー （グアンジョウ） カンパニー リミテッド | 注射用ドセタキセル組成物およびそのための調製法 |
| CA3217204A1 (en) * | 2021-05-26 | 2022-12-01 | Daewoong Pharmaceutical Co., Ltd. | New formulation for injection comprising 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n-methylmethanamine |
| CN115960834B (zh) * | 2023-03-07 | 2023-06-09 | 浙江省肿瘤医院 | 一种pd-1/ptx联合pd-1耐药模型建立的方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5602112A (en) * | 1992-06-19 | 1997-02-11 | Supergen, Inc. | Pharmaceutical formulation |
| JPH06157330A (ja) * | 1992-11-27 | 1994-06-03 | Ensuiko Sugar Refining Co Ltd | タキソールのサイクロデキストリン包接物，その製造法と用途 |
| JPH0753396A (ja) * | 1993-08-19 | 1995-02-28 | Ensuiko Sugar Refining Co Ltd | タキソールのサイクロデキストリン包接物，その製造法および用途 |
| HU213200B (en) * | 1993-05-12 | 1997-03-28 | Chinoin Gyogyszer Es Vegyeszet | The cyclodextrin or cyclodextrin derivative cluster complexes of taxol, taxotere, or taxus, pharmaceutical preparations containing them and process for their production |
| DE4414138A1 (de) * | 1994-04-22 | 1995-10-26 | Consortium Elektrochem Ind | Acylierte gamma-Cyclodextrine |
| HUT73844A (en) * | 1994-11-11 | 1996-09-30 | Chinoin Gyogyszer Es Vegyeszet | New taxol complexes and pharmaceutical compositions containing them |
| CA2163837C (en) * | 1994-12-13 | 1999-07-20 | Robert K. Perrone | Crystalline paclitaxel hydrates |
| IL161372A0 (en) * | 2001-11-30 | 2004-09-27 | Bristol Myers Squibb Co | Crystalline solvates of paclitaxel |
-
1997
- 1997-11-10 HU HU9701945A patent/HUP9701945A3/hu unknown
-
1998
- 1998-10-27 ZA ZA989779A patent/ZA989779B/xx unknown
- 1998-11-06 AR ARP980105607A patent/AR015482A1/es unknown
- 1998-11-09 IL IL13599098A patent/IL135990A0/xx unknown
- 1998-11-09 CN CNB988110105A patent/CN1222321C/zh not_active Expired - Fee Related
- 1998-11-09 JP JP2000520158A patent/JP3656550B2/ja not_active Expired - Fee Related
- 1998-11-09 CA CA2309326A patent/CA2309326C/en not_active Expired - Fee Related
- 1998-11-09 AU AU12538/99A patent/AU742036B2/en not_active Ceased
- 1998-11-09 EP EP98955818A patent/EP1059942B1/en not_active Expired - Lifetime
- 1998-11-09 BR BR9814015-9A patent/BR9814015A/pt not_active Application Discontinuation
- 1998-11-09 PL PL340505A patent/PL199652B1/pl not_active IP Right Cessation
- 1998-11-09 KR KR1020007005076A patent/KR100607391B1/ko not_active IP Right Cessation
- 1998-11-09 NZ NZ504098A patent/NZ504098A/xx not_active IP Right Cessation
- 1998-11-09 WO PCT/HU1998/000097 patent/WO1999024073A1/en active IP Right Grant
- 1998-11-09 AT AT98955818T patent/ATE387916T1/de active
- 1998-11-09 EA EA200000494A patent/EA002776B1/ru not_active IP Right Cessation
- 1998-11-09 DE DE69839224T patent/DE69839224T2/de not_active Expired - Lifetime
-
2000
- 2000-04-27 NO NO20002165A patent/NO329382B1/no not_active IP Right Cessation
-
2006
- 2006-10-04 US US11/542,797 patent/US7671042B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EA200000494A1 (ru) | 2000-10-30 |
| NO20002165D0 (no) | 2000-04-27 |
| EP1059942B1 (en) | 2008-03-05 |
| AU1253899A (en) | 1999-05-31 |
| CA2309326A1 (en) | 1999-05-20 |
| US20070087999A1 (en) | 2007-04-19 |
| DE69839224D1 (de) | 2008-04-17 |
| PL340505A1 (en) | 2001-02-12 |
| NZ504098A (en) | 2003-06-30 |
| WO1999024073B1 (en) | 1999-07-08 |
| DE69839224T2 (de) | 2009-04-16 |
| HUP9701945A3 (en) | 2000-04-28 |
| CN1222321C (zh) | 2005-10-12 |
| IL135990A0 (en) | 2001-05-20 |
| CN1281373A (zh) | 2001-01-24 |
| HUP9701945A1 (hu) | 1999-09-28 |
| AU742036B2 (en) | 2001-12-13 |
| US7671042B2 (en) | 2010-03-02 |
| CA2309326C (en) | 2010-12-21 |
| JP3656550B2 (ja) | 2005-06-08 |
| ATE387916T1 (de) | 2008-03-15 |
| NO329382B1 (no) | 2010-10-04 |
| ZA989779B (en) | 1999-04-28 |
| PL199652B1 (pl) | 2008-10-31 |
| EA002776B1 (ru) | 2002-08-29 |
| WO1999024073A1 (en) | 1999-05-20 |
| NO20002165L (no) | 2000-07-07 |
| HU9701945D0 (en) | 1998-01-28 |
| BR9814015A (pt) | 2000-09-26 |
| KR100607391B1 (ko) | 2006-08-02 |
| JP2001522816A (ja) | 2001-11-20 |
| KR20010031967A (ko) | 2001-04-16 |
| EP1059942A2 (en) | 2000-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR015482A1 (es) | Una composicion farmaceutica solida y soluble en agua que contiene un taxoide y una ciclodextrina, sus soluciones en disolventes acuosos para usoparenteral, un procedimiento para su preparacion, un metodo para prevenir la autoagregacion y la precipitacion prematura de un taxoide del grupo delpaclita | |
| CY1114631T1 (el) | Φαρμακοτεχνικες μορφες εχινοκανδινης που περιεχουν επιφανειοδραστικα που σχηματιζουν μικκυλιο | |
| NO20100302L (no) | Sammensetninger som inneholder organiske forbindelser | |
| ES2178268T3 (es) | Formulaciones de liberacion controlada. | |
| AR025959A1 (es) | DERIVADOS DE TER.-BUTIL-(7-METIL-IMIDAZO[1,2,a]PIRIDIN-3-IL)-AMINA, PROCEDIMIENTO PARA SU PREPARACION, MEDICAMENTOS QUE LOS CONTIENEN, SU USO PARA LAPREPARACION DE UN MEDICAMENTO PARA LA INHIBICION DE NO-SINTASA Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN | |
| CO4810223A1 (es) | Composiciones de champu estilizantes | |
| SV2004001556A (es) | Preparaciones acidas de insulina con establidad mejorada | |
| AR008927A1 (es) | Una composicion farmaceutica que comprende una sustancia medicinalmente activa insoluble en agua con propiedades mejoradas de disolucion, absorcion, etc., y el procedimiento para prepararla | |
| PE87199A1 (es) | Un polisacarido modificado hidrofobicamente para productos del cuidado personal | |
| BR0107147A (pt) | Composições farmacêuticas de drogas anti-tuberculosas e processo para as suas preparações | |
| CY1106542T1 (el) | Μεθοδος για παρασκευη φαρμακευτικων συνθεσεων για χρηση με συνταγοποιησεις μαλακης ζελατινης | |
| AR019114A1 (es) | Nuevas microesferas a base de poli(metiliden malonato), su procedimiento de preparacion y composiciones farmaceuticas que las contienen | |
| PT731688E (pt) | Formulacoes de farmacos em aerossol para utilizacao com propulsores sem cfc | |
| DE69825116D1 (de) | Transdermale verabreichung basischer wirkstoffe unter verwendung unpolarer haftsysteme und saurer lösungsvermittler | |
| ES2137350T3 (es) | Formulacion farmaceutica. | |
| PE20070377A1 (es) | Formulaciones liquidas para la administracion controlada de derivados de bencisoxazol | |
| CO5160287A1 (es) | Formulacion de liberacion controlada de divalproex sodico | |
| CO5560533A2 (es) | Preparacion de una composicion farmaceutica de liberacion sostenida | |
| ES2194736T3 (es) | Sistema de microdepositos sobre la base de polisiloxanos y disolvente ambifilos. | |
| PE20001326A1 (es) | Composicion farmaceutica que comprende cefuroxima-axetil, polimero y/o adsorbente | |
| SV2002000301A (es) | Composicion farmaceutica ref. z-1032 | |
| AR024476A1 (es) | Uso de derivados de acido benzacepin-n-acetico, para la elaboracion de preparados farmaceuticos para la profilaxis y/o tratamiento de lesiones cardiacasprocedimiento para su preparacion y productos que los contienen. | |
| AR009651A1 (es) | Composicion solubilizante/estabilizante anhidra, emulsionable o microemulsionable en agua, para la solubilizacion de los derivados hidrofobosde n-sulfonil indolina, composicion farmaceutica microemulsionable o emulsionable en medio acuoso, y capsulas farmaceuticas, particularmente blandas | |
| IT1309584B1 (it) | Peptidi immunogenici derivati da mage-3 presentati da mhc di classeii e loro uso. | |
| ES2199094T1 (es) | Polimeros formadores de pelicula, procedimientos de uso y aplicaciones de los mismos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |